Most of us know AI tools as assistants that draft emails or write computer code. Now, the company behind Claude, one of the most prominent AI models, wants to apply that same technology to the notoriously slow and expensive world of drug discovery. Anthropic recently announced a new workspace designed to help scientists manage massive amounts of research data and generate visual charts. But more importantly, the company says it plans to start developing its own medical treatments, specifically targeting neglected diseases.
Anthropic is pivoting toward being a drug manufacturer as well as a software provider. By creating a specialized workbench for scientists, it wants to help researchers piece together scattered datasets to identify potential treatments more quickly. Simultaneously, the company is hiring biologists and building its own laboratory facilities. This makes them a direct competitor to the pharmaceutical companies that happen to be their own customers. While the company has shared its ambition, it has provided few details on which diseases it will target or how it plans to handle the later stages of development, like human trials.
The reality of biology vs. software
To understand why this is a challenge, it helps to distinguish between a search and an experiment. Modern AI is excellent at pattern recognition. Imagine you have a library containing every known chemical structure and millions of research papers. An AI model acts like a hyper-efficient librarian; it can quickly cross-reference massive databases to suggest new combinations of molecules that might interact with a specific disease marker in the body. This is a massive shortcut for the early research phase, where scientists typically spend years guessing which chemical paths to explore.
However, suggesting a potential drug is only the first step. You cannot simulate the complexity of a human body with code alone. Once the AI suggests a candidate molecule, it must be created in a physical lab and tested repeatedly for efficacy, safety, and toxicity. It must also be stable enough to be stored and then delivered into a living system. AI can narrow the field of candidates, but it has not yet eliminated the need for wet labs—facilities where scientists wear protective gear and watch chemicals interact in beakers and petri dishes. If a drug is toxic to the liver or simply doesn't get absorbed by the body, no amount of AI-generated data can change that outcome. You have to go back to the drawing board.
The hype surrounding AI in medicine often misses the most difficult part of the process: the time it takes to prove safety. Even when AI accelerates the initial discovery phase, a new drug must still pass through years of clinical trials before it is approved for public use. There is no shortcut for human biology. While Anthropic’s entry into this space suggests more resources are flowing into the field, we are likely a decade away from seeing if an AI-designed drug can actually outperform traditional methods. For now, AI is a powerful compass for navigating a vast sea of possibilities, but humans must still build and captain the actual ship.
Liked this one? The next lands at breakfast.
Every story in tomorrow's AI news, rebuilt in plain English — five minutes, sources linked, free forever.
By joining you agree to receive Article's daily newsletter — unsubscribe in one click. Privacy